A gender-based secondary analysis of the ADAPT-2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial.

Ximena A LevanderThomas CarmodyRyan R CookJennifer S PotterMadhukar H Trivedi Philip Todd Korthuis Steven J Shoptaw

Published in: Addiction (Abingdon, England) (2023)

Women with methamphetamine use disorder receiving combined intramuscular naltrexone and oral bupropion treatment achieve greater treatment response than placebo. Treatment effect does not differ by HMC.

Keyphrases

randomized controlled trial
mental health
phase iii
replacement therapy